{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2011:EDLGHHO2JUOIWHCEFHVYEDJY5K","short_pith_number":"pith:EDLGHHO2","canonical_record":{"source":{"id":"1108.1614","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2011-08-08T07:12:21Z","cross_cats_sorted":[],"title_canon_sha256":"7966f96a21267a5c92fc101bedf2f0c43f4158eb7295b15d0d82fef266079409","abstract_canon_sha256":"1c71073508face53ba5ca6c62748e88e25feac91ab3fab9b070a67a905da26bf"},"schema_version":"1.0"},"canonical_sha256":"20d6639dda4d1c8b1c4429eb820d38ea8754e534c4c8578692a3334c76e04f36","source":{"kind":"arxiv","id":"1108.1614","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1108.1614","created_at":"2026-05-18T04:16:00Z"},{"alias_kind":"arxiv_version","alias_value":"1108.1614v1","created_at":"2026-05-18T04:16:00Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1108.1614","created_at":"2026-05-18T04:16:00Z"},{"alias_kind":"pith_short_12","alias_value":"EDLGHHO2JUOI","created_at":"2026-05-18T12:26:28Z"},{"alias_kind":"pith_short_16","alias_value":"EDLGHHO2JUOIWHCE","created_at":"2026-05-18T12:26:28Z"},{"alias_kind":"pith_short_8","alias_value":"EDLGHHO2","created_at":"2026-05-18T12:26:28Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2011:EDLGHHO2JUOIWHCEFHVYEDJY5K","target":"record","payload":{"canonical_record":{"source":{"id":"1108.1614","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2011-08-08T07:12:21Z","cross_cats_sorted":[],"title_canon_sha256":"7966f96a21267a5c92fc101bedf2f0c43f4158eb7295b15d0d82fef266079409","abstract_canon_sha256":"1c71073508face53ba5ca6c62748e88e25feac91ab3fab9b070a67a905da26bf"},"schema_version":"1.0"},"canonical_sha256":"20d6639dda4d1c8b1c4429eb820d38ea8754e534c4c8578692a3334c76e04f36","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T04:16:00.577478Z","signature_b64":"h4bqiKqdeF9QcC+0jYSlIa6RoJ/bV+1PQMISZgR+DpTjOkcJ4IdarDQTPhlBedsdCxPlK1fmWAQ3/T4PhIdZAA==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"20d6639dda4d1c8b1c4429eb820d38ea8754e534c4c8578692a3334c76e04f36","last_reissued_at":"2026-05-18T04:16:00.576900Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T04:16:00.576900Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1108.1614","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T04:16:00Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"Vi1pECn9GusR+1cn4WY66CuskvGFVID7FnP5lv/5syYFCelJQr7/6RItcuO0umHpk5y5w9/zwGe2lTj8KcU2CQ==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-07-01T18:35:13.239555Z"},"content_sha256":"fde9b5caa12185d3314cb8dbc3616dc352885cfdb4942ee91bd7df0a1398ff16","schema_version":"1.0","event_id":"sha256:fde9b5caa12185d3314cb8dbc3616dc352885cfdb4942ee91bd7df0a1398ff16"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2011:EDLGHHO2JUOIWHCEFHVYEDJY5K","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Bayesian phase I/II adaptively randomized oncology trials with combined drugs","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"stat.AP","authors_text":"Guosheng Yin, Ying Yuan","submitted_at":"2011-08-08T07:12:21Z","abstract_excerpt":"We propose a new integrated phase I/II trial design to identify the most efficacious dose combination that also satisfies certain safety requirements for drug-combination trials. We first take a Bayesian copula-type model for dose finding in phase I. After identifying a set of admissible doses, we immediately move the entire set forward to phase II. We propose a novel adaptive randomization scheme to favor assigning patients to more efficacious dose-combination arms. Our adaptive randomization scheme takes into account both the point estimate and variability of efficacy. By using a moving refe"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1108.1614","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T04:16:00Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"UEqUHH+f0coAPJwjRa010cCk4kgU3q6s3ZSSrKwYSmJp18CcKg3zVPT8ISLlacI7r+/QvSukk4KAeOk1WQHhCQ==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-07-01T18:35:13.239887Z"},"content_sha256":"78cefc2e15189e54a817c2e1ad1e54e5a6c8b283b917039e1aaecbc3dbf4ecdd","schema_version":"1.0","event_id":"sha256:78cefc2e15189e54a817c2e1ad1e54e5a6c8b283b917039e1aaecbc3dbf4ecdd"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/EDLGHHO2JUOIWHCEFHVYEDJY5K/bundle.json","state_url":"https://pith.science/pith/EDLGHHO2JUOIWHCEFHVYEDJY5K/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/EDLGHHO2JUOIWHCEFHVYEDJY5K/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-07-01T18:35:13Z","links":{"resolver":"https://pith.science/pith/EDLGHHO2JUOIWHCEFHVYEDJY5K","bundle":"https://pith.science/pith/EDLGHHO2JUOIWHCEFHVYEDJY5K/bundle.json","state":"https://pith.science/pith/EDLGHHO2JUOIWHCEFHVYEDJY5K/state.json","well_known_bundle":"https://pith.science/.well-known/pith/EDLGHHO2JUOIWHCEFHVYEDJY5K/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2011:EDLGHHO2JUOIWHCEFHVYEDJY5K","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"1c71073508face53ba5ca6c62748e88e25feac91ab3fab9b070a67a905da26bf","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2011-08-08T07:12:21Z","title_canon_sha256":"7966f96a21267a5c92fc101bedf2f0c43f4158eb7295b15d0d82fef266079409"},"schema_version":"1.0","source":{"id":"1108.1614","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1108.1614","created_at":"2026-05-18T04:16:00Z"},{"alias_kind":"arxiv_version","alias_value":"1108.1614v1","created_at":"2026-05-18T04:16:00Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1108.1614","created_at":"2026-05-18T04:16:00Z"},{"alias_kind":"pith_short_12","alias_value":"EDLGHHO2JUOI","created_at":"2026-05-18T12:26:28Z"},{"alias_kind":"pith_short_16","alias_value":"EDLGHHO2JUOIWHCE","created_at":"2026-05-18T12:26:28Z"},{"alias_kind":"pith_short_8","alias_value":"EDLGHHO2","created_at":"2026-05-18T12:26:28Z"}],"graph_snapshots":[{"event_id":"sha256:78cefc2e15189e54a817c2e1ad1e54e5a6c8b283b917039e1aaecbc3dbf4ecdd","target":"graph","created_at":"2026-05-18T04:16:00Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"We propose a new integrated phase I/II trial design to identify the most efficacious dose combination that also satisfies certain safety requirements for drug-combination trials. We first take a Bayesian copula-type model for dose finding in phase I. After identifying a set of admissible doses, we immediately move the entire set forward to phase II. We propose a novel adaptive randomization scheme to favor assigning patients to more efficacious dose-combination arms. Our adaptive randomization scheme takes into account both the point estimate and variability of efficacy. By using a moving refe","authors_text":"Guosheng Yin, Ying Yuan","cross_cats":[],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2011-08-08T07:12:21Z","title":"Bayesian phase I/II adaptively randomized oncology trials with combined drugs"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1108.1614","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:fde9b5caa12185d3314cb8dbc3616dc352885cfdb4942ee91bd7df0a1398ff16","target":"record","created_at":"2026-05-18T04:16:00Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"1c71073508face53ba5ca6c62748e88e25feac91ab3fab9b070a67a905da26bf","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2011-08-08T07:12:21Z","title_canon_sha256":"7966f96a21267a5c92fc101bedf2f0c43f4158eb7295b15d0d82fef266079409"},"schema_version":"1.0","source":{"id":"1108.1614","kind":"arxiv","version":1}},"canonical_sha256":"20d6639dda4d1c8b1c4429eb820d38ea8754e534c4c8578692a3334c76e04f36","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"20d6639dda4d1c8b1c4429eb820d38ea8754e534c4c8578692a3334c76e04f36","first_computed_at":"2026-05-18T04:16:00.576900Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T04:16:00.576900Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"h4bqiKqdeF9QcC+0jYSlIa6RoJ/bV+1PQMISZgR+DpTjOkcJ4IdarDQTPhlBedsdCxPlK1fmWAQ3/T4PhIdZAA==","signature_status":"signed_v1","signed_at":"2026-05-18T04:16:00.577478Z","signed_message":"canonical_sha256_bytes"},"source_id":"1108.1614","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:fde9b5caa12185d3314cb8dbc3616dc352885cfdb4942ee91bd7df0a1398ff16","sha256:78cefc2e15189e54a817c2e1ad1e54e5a6c8b283b917039e1aaecbc3dbf4ecdd"],"state_sha256":"99ca8e3f054c1b867574862ca559a4644858ce5897a4e3e5bc44bd87fcaa40fe"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"SZhFrS1fE1ch0F4gKTVDe3WlVBC1x3IOUwO8qnTcIcfDxjHO6+h9KjyY+M/kS1W7EGypmrPSO4ZTiolA3ZluCQ==","signed_message":"bundle_sha256_bytes","signed_at":"2026-07-01T18:35:13.241762Z","bundle_sha256":"bbfc0120caff2544af83134465344e3a031a5b0168566481f2ea7542e8d3fd65"}}